Skip to content
Menu

Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsInitiationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.

Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.

Read at benzinga.com